| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Wahlbeck, M Cheine, A Essali, C Adam. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401441. |
the purpose of this study was to evaluate all available trial-based evidence on the effectiveness of clozapine in schizophrenia as compared with conventional neuroleptics. |
1999-07-30 |
2023-08-12 |
Not clear |
| V Kumari, W Soni, T Sharm. Normalization of information processing deficits in schizophrenia with clozapine. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401450. |
normalization of information processing deficits in schizophrenia with clozapine. |
1999-07-30 |
2023-08-12 |
Not clear |
| V Kumari, W Soni, T Sharm. Normalization of information processing deficits in schizophrenia with clozapine. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401450. |
the authors tested the hypothesis that the use of an atypical drug, clozapine, for patients with schizophrenia is related to less impairment in information processing deficits (assessed by prepulse inhibition of the startle response) than is the use of typical antipsychotics. |
1999-07-30 |
2023-08-12 |
Not clear |
| H Y Meltze. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401484. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Rubi. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401485. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| E Dunayevich, A Chatterje. Risperidone and clozapine for treatment-resistant schizophrenia. The American journal of psychiatry. vol 156. issue 7. 1999-07-30. PMID:10401486. |
risperidone and clozapine for treatment-resistant schizophrenia. |
1999-07-30 |
2023-08-12 |
Not clear |
| A I Green, S V Zimmet, R D Strous, J J Schildkrau. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard review of psychiatry. vol 6. issue 6. 1999-07-29. PMID:10370435. |
clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? |
1999-07-29 |
2023-08-12 |
Not clear |
| A I Green, S V Zimmet, R D Strous, J J Schildkrau. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard review of psychiatry. vol 6. issue 6. 1999-07-29. PMID:10370435. |
we further suggest that clozapine's beneficial effect in patients with comorbid schizophrenia and substance use disorders may relate to its presumed ability to ameliorate the deficits in both the mesocortical and mesolimbic dopaminergic neuronal projections through its various actions on dopaminergic, serotonergic, and particularly noradrenergic neurons. |
1999-07-29 |
2023-08-12 |
Not clear |
| D A Revick. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia research. vol 35 Suppl. 1999-07-21. PMID:10190231. |
the current pharmacoeconomic evidence suggests that clozapine is a cost-effective therapy for neuroleptic-refractory schizophrenia and that although olanzapine and risperidone therapy may be cost neutral, they improve outcome in patients treated for schizophrenia. |
1999-07-21 |
2023-08-12 |
Not clear |
| D A Wirshing, W C Wirshing, L Kysar, M A Berisford, D Goldstein, J Pashdag, J Mintz, S R Marde. Novel antipsychotics: comparison of weight gain liabilities. The Journal of clinical psychiatry. vol 60. issue 6. 1999-07-13. PMID:10401912. |
we performed a retrospective analysis of 122 clinical records of 92 male patients with dsm-iii-r schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol. |
1999-07-13 |
2023-08-12 |
Not clear |
| L de Haan, D H Linszen, R Gorsir. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. The Journal of clinical psychiatry. vol 60. issue 6. 1999-07-13. PMID:10401913. |
clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. |
1999-07-13 |
2023-08-12 |
Not clear |
| L de Haan, D H Linszen, R Gorsir. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. The Journal of clinical psychiatry. vol 60. issue 6. 1999-07-13. PMID:10401913. |
the increase or emergence of obsessions was compared in young patients with recent-onset schizophrenia or other psychotic disorders taking clozapine and other antipsychotic drugs. |
1999-07-13 |
2023-08-12 |
Not clear |
| N Bergemann, C Ehrig, K Diebold, C Mundt, R von Einsiede. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry. vol 32. issue 2. 1999-07-09. PMID:10333168. |
we report a case of asymptomatic pancreatitis subsequent to clozapine treatment at therapeutic doses in a 38-year-old male patient with chronic paranoid-hallucinatory schizophrenia. |
1999-07-09 |
2023-08-12 |
Not clear |
| H Hippiu. A historical perspective of clozapine. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372606. |
having challenged the established view that extrapyramidal symptoms are an intrinsic feature of antipsychotic activity, clozapine was developed as the first atypical antipsychotic with activity against both the positive and negative symptoms of schizophrenia. |
1999-06-24 |
2023-08-12 |
Not clear |
| H Hippiu. A historical perspective of clozapine. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372606. |
this article outlines the history of clozapine's development, from its discovery in 1958 to its current position as the "gold standard" therapy for treatment-resistant schizophrenia. |
1999-06-24 |
2023-08-12 |
Not clear |
| S R McGur. The effects of clozapine on cognitive functioning in schizophrenia. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372607. |
the effects of clozapine on cognitive functioning in schizophrenia. |
1999-06-24 |
2023-08-12 |
Not clear |
| S R McGur. The effects of clozapine on cognitive functioning in schizophrenia. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372607. |
however, there is evidence that the atypical antipsychotic clozapine may improve this core deficit of schizophrenia. |
1999-06-24 |
2023-08-12 |
Not clear |
| S R McGur. The effects of clozapine on cognitive functioning in schizophrenia. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372607. |
such cognitive improvements with clozapine treatment may offer an advantage to patients with schizophrenia by enhancing the possibility of better vocational functioning and quality of life. |
1999-06-24 |
2023-08-12 |
Not clear |
| L D Alphs, R Anan. Clozapine: the commitment to patient safety. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372610. |
clozapine represents the "gold standard" therapy for treatment-resistant schizophrenia including use for symptom reduction and use in patients intolerant of extrapyramidal side effects associated with other antipsychotics. |
1999-06-24 |
2023-08-12 |
Not clear |
| J Volavk. The effects of clozapine on aggression and substance abuse in schizophrenic patients. The Journal of clinical psychiatry. vol 60 Suppl 12. 1999-06-24. PMID:10372611. |
after 6 months of treatment with clozapine, substance abusers and nonabusers with schizophrenia or schizoaffective disorder showed similar improvements on measures of psychopathology and psychosocial functioning. |
1999-06-24 |
2023-08-12 |
Not clear |